Completed PHASE2 INTERVENTIONAL 1-arm NCT00579423

Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate Cancer

A Pilot Multivalent Conjugate Vaccine Trial for Patients With Biochemically Relapsed Prostate Cancer

Sponsor: Capcure

Interventions QS21

Updated 7 times since 2017 Last updated: Oct 4, 2023 Started: Nov 30, 2000 Primary completion: May 31, 2003 Completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cancer and Prostate and is currently completed. Capcure leads this study, which shows 7 recorded versions since 2000 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Nov 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Nov 2023 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Capcure
Memorial Sloan Kettering Cancer Center

Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States